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The rapid increase in the number of monoclonal antibodies (mAbs) which are being regularly 
approved for therapeutic use results in the need of their large scale production. However, this 
requires the development of bioreactors and processes simple to operate and easily scaled-
up, that allow cultivation of mammalian cells. The Stirred Tank bioreactor is the traditional 
and most widely used reactor type, mainly due to the know-how acquired with microbial 
fermentation, its flexibility and suitability for different cell types, operation modes, products 
and working volumes.[1] However, recently, disposable bioreactors, such as the new Wave 
reactor, are becoming increasingly popular due to their low initial and lifetime costs, 
simplified scale-up, reduced turn-around time between runs and low risk of cross-
contamination.[2]  
Due to the current lack of comparative studies about these different technologies, we are 
optimizing and comparing mAb production in both Stirred Tank and Wave bioreactors. 
Different modes of operation are being tested (batch and fed-batch), and the use of 
microcarrier technology for culture of anchorage-dependent cells will also be assayed. 
Furthermore, it is important to evaluate the product in terms of biological activity, assuring 
that it maintains full functionality, by assessing how the glycosylation pattern is affected 
during the process of production in both reactors.  
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